|View printer-friendly version|
|October 27, 2003 4:48 p.m.|
|Teva Receives Favorable Court Ruling On Fosinopril Sodium Tablets|
Jerusalem, Israel, October 27, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of New York has granted judgment in favor of Teva, ruling that the company's Abbreviated New Drug Application (ANDA) for Fosinopril Sodium Tablets, 10 mg, 20 mg and 40 mg, a generic version of Bristol-Myers Squibb's Monopril® Tablets, does not infringe U.S. Patent No. 5,006,344. The ruling follows the completion of a trial last May.